samplefor weight loss
98%+ · 5mg · Lyophilized
Bulk discount
3+ pcs
€47.50
−5%
5+ pcs
€45.00
−10%
10+ pcs
€42.50
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Semaglutide
GLP-1 Receptor Agonist | Weight Loss & Diabetes
In short
Long-acting GLP-1 receptor agonist studied in large-scale clinical models of obesity and glucose homeostasis.
Best sellers
Education
Related resources
Ready-to-use starter kit
Semaglutide is a synthetic peptide consisting of 32 amino acids that structurally mimics the naturally occurring human GLP-1 hormone. At the molecular level, it functions as an agonist by binding to GLP-1 receptors and triggering signaling pathways associated with insulin regulation. Researchers study this molecule primarily in in vitro settings and animal models to observe its mechanisms related to metabolic processes. While semaglutide is the active pharmaceutical ingredient in approved prescription medications (such as Ozempic® and Wegovy®), this specific product is a research-grade chemical and is strictly not a medicine for human consumption.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes management (as Ozempic injectable or Rybelsus oral) and chronic weight management (as Wegovy injectable or oral). In December 2025, oral Wegovy became the first oral GLP-1 approved for weight management, offering a 25mg daily tablet option alongside the established injectable. With over 17,000 participants in clinical trials, semaglutide demonstrates significant weight loss potential (average 15-20% body weight reduction) through appetite suppression, slowed gastric emptying, and enhanced glucose control.
14.9% body-weight reduction over 68 weeks at 2.4 mg (STEP-1, NEJM 2021) ~165h half-life enables weekly dosing Tri-tissue effect: β-cells + hypothalamus + stomach Reduced hedonic feeding motivation (fMRI mesolimbic) GLP-1R agonist gold standard for research
Subcutaneous semaglutide mimics native GLP-1, binding to GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic pathways. The 7-day half-life allows weekly dosing.
FDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials
Reduces hunger and food cravings through central nervous system GLP-1 receptor activation
Long-term studies show maintained weight loss with continued treatment over 2+ years
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Any time of day, with or without food
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 10
10marks
Standard insulin syringe 1 ml (100 marks)
Concentration
2.50mg/ml
Dose volume
0.100ml
U-100 units
10units
Doses per vial
20doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (5 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Any time of day, with or without food
If using pre-filled pen, attach new needle and prime according to instructions
If using vial, draw prescribed dose with appropriate syringe
Clean injection site with alcohol swab and let dry
Inject subcutaneously at 90-degree angle (45-degree if lean)
Hold for 6 seconds after injection to ensure full dose delivery
Dispose of needle safely and rotate injection sites weekly
Nausea
common·STEP 1
Vomiting
common·STEP 1
Diarrhea
common·STEP 1
Constipation
common·STEP 1
Reduced appetite / early satiety
common
Headache
uncommon
Pancreatitis (rare, requires discontinuation)
rare
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
OASIS 4 Oral Semaglutide for Weight Management (2025)
307 participants | 25mg daily | 64 weeks | ~14% weight loss (~33 lb) vs 2.4% placebo
Pivotal Phase III trial supporting FDA approval of oral Wegovy. Adults with obesity or overweight (with at least one weight-related condition) lost on average ~14% of starting body weight (~33 lb from 235 lb) vs 2.4% (~6 lb) with placebo, alongside reduced-calorie diet and increased physical activity. 76% achieved ≥5% weight loss (vs 31% placebo), 60% achieved ≥10% (vs 14%), 47% achieved ≥15% (vs 6%), and 28% achieved ≥20% (vs 3%). Adults with type 2 diabetes were excluded. 18% of Wegovy pill participants discontinued vs 26% on placebo.
SELECT Cardiovascular Outcomes (2023)
17,604 participants | 2.4mg weekly | 5 years | 20% CV risk reduction
Major cardiovascular outcomes trial demonstrating 20% reduction in major adverse cardiovascular events in overweight/obese adults with established CVD.
STEP 5 Two-Year Maintenance (2022)
304 participants | 2.4mg weekly | 104 weeks | Sustained weight loss
Two-year study confirming sustained weight loss (15.2% at week 104) with continued treatment, demonstrating long-term efficacy.
STEP TEENS Adolescent Study (2022)
201 adolescents | 2.4mg weekly | 68 weeks | 16.1% BMI reduction
First trial in adolescents (12-17 years) with obesity showing significant BMI reduction and metabolic improvements.
STEP 1 Trial - Weight Management (2021)
1,961 participants | 2.4mg weekly | 68 weeks | 14.9% weight loss
Landmark phase 3 trial in adults with obesity showing 14.9% average weight loss with semaglutide 2.4mg versus 2.4% with placebo, establishing efficacy for weight management.
PIONEER Oral Semaglutide (2019)
9,543 participants | 3-14mg daily | 26-78 weeks | Oral efficacy
Series of trials establishing oral semaglutide efficacy for diabetes with HbA1c reductions comparable to injectable GLP-1 agonists.
SUSTAIN Diabetes Program (2016-2019)
Multiple trials | 0.5-1mg weekly | Various durations | HbA1c reduction
Comprehensive clinical program establishing efficacy for type 2 diabetes with average HbA1c reductions of 1.5-1.8% across trials.
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
